Scioto Biosciences

Scioto is a preclinical stage company developing innovative therapies devoted to having a transformative impact.

Scioto Biosciences is a business in food & beverage based in United States.

Profile

"Scioto Biosciences is a pioneering health and lifetech company focused on developing innovative therapies with a transformative impact on microbiome therapeutics. Founded in 2017 and headquartered in Indianapolis, Indiana, Scioto Biosciences is dedicated to revolutionizing the delivery of microbiome-based treatments. At the core of their mission is the Scioto Platform, designed to enhance the efficacy of probiotics in various applications, including diabetes, neurological disorders, gastrointestinal health, and livestock health. Central to Scioto's advancements is their proprietary Activated Bacterial Therapeutics (ABT) platform, which optimizes the delivery and functionality of live bacterial therapeutics. Their lead product candidate, SB-121, utilizes this platform to target specific conditions like Autism Spectrum Disorder and necrotizing enterocolitis. In 2020, Scioto Biosciences secured a significant Series B investment from Genome & Company, a South Korean firm, further solidifying their position in the industry and expanding their developmental capabilities."

Within the food & beverage space, the company focuses on its core offering rather than a broad product line.

The business is associated with United States.

Directory data places it at the Plug and Play accelerated startup stage.

Website: sciotobiosciences.com